-
MEXIDOL® (Emoxipine) 125 mg, 50 coated tablets
$17.00
$22.00 -
ARPEFLU (Umifenovir) 100 mg, 20/30 caps
$24.00 – $33.00
Lokatop 0.1% 30g of the cream for external use in a tube
$19.00
Description
The instruction for medical use of Lokatop medicine of 0.1% the International unlicensed name Desonid Lekarstvennaya a form external use Cream Structure Each 100 g of cream contain the Trade name of the drug Lokatop of 0.1%: active agent – desonid 0.1 g, excipients: vaseline, liquid paraffin, cetostearyl alcohol and cetostearyl ether of a macrogoal 1000, propyl gallate, sodium edetat, sorbic acid, the water purified. The description Uniform cream of white color, flavourless Pharmacotherapeutic group Glucocorticosteroids for topical treatment of diseases of skin. Glucocorticosteroids with moderate activity. Desonid. The ATX D07AB08 code the Pharmacological Pharmacokinetics Degree properties of transdermalny passings and system effects depends on the processed surface, extent of change of epidermis and duration of treatment. It is necessary to be afraid of these effects especially at long-term treatment. A pharmacodynamics the Local glucocorticoid (class II according to skin tests of vasoconstriction). Has anti-inflammatory, vasoconstrictive effect. Induces formation of the lipokortin inhibiting activity of a phospholipase of A2, slows down synthesis of prostaglandins and leukotrienes. Reduces permeability of vessels, a chemotaxis, promotes stabilization of lysosomes. Indications – contact eczema – atopic dermatitis – a likhenization – kongestivny dermatitis – – herpeses – not parasitic prurigo – scleroatrophic genital deprive psoriasis (except for very big plaques) – a ring-shaped granuloma – a diskoidny lupus erythematosus – not microbic palmar and bottom pustulez – seborrheal dermatitis, except its localization on a face – symptomatic treatment of an itching of fungal mycoses – stings/pricks of insects and parasitic prurigo after etiopatogenetichesky treatment the Route of administration and doses Lokatop of 0.1% needs to be applied with easy massage movements on affected areas no more than 2 times a day. Putting drug over the established norm can lead to side effects without therapeutic effect. Treatment of big sites demands monitoring of quantity of the used tubas. It is recommended to apply drug with small doses at distance from each other, then to pound on skin (using a plastic glove) before its full absorption in skin. Gradual phase-out Lokatop of 0.1% is recommended at some dermatosis (psoriasis, atopic dermatitis, etc.), by reduction of frequency of use and/or by means of less active and concentrated glucocorticoids. Side effects Often: – a skin atrophy – a telangiectasia (especially localization on a face) – strata (in particular, on proximal departments of extremities which proyavlyavlyatsya quicker at youthful age) – an ekkhimotichesky purpura – perioral dermatitis – emergence or aggravation of a rozatsea – a delay of healing of wounds, decubituses and slow ulcers Standing seldom: – acne or pustulous rashes, a hypertrichosis, a depigmentation – consecutive infections, especially at occlusive bandages or in skin folds – an allergic contact dermatosis of the Contraindication – hypersensitivity to any of drug components – primary bacterial, viral or fungal infection or parasitic infections – cankers in the site of application of drug – an acne – rozatseya – pregnancy and the period of a lactation – children’s age up to 2 years Medicinal interactions Desonid does not render clinically significant interaction with other medicines at use in the recommended doses. Can result the special instructions Drug Use Cancellation at prolonged use of corticosteroids in risk of a withdrawal. In this case gradual cancellation of use of drug is necessary. Corticosteroids getting into a system blood stream can result in system effects (Cushing’s syndrome, growth delay, etc.), especially at babies and children of younger age up to 2 years. These effects disappear at treatment cancellation, but sharp cancellation can be followed by acute adrenal insufficiency. It is recommended to avoid use of corticosteroids (class I and II) for children up to 2 years. It is necessary to be careful of spontaneous occlusion which can arise pleated skins and under diapers. In case of a bacterial or fungal infection of a kortiko-sensitive dermatosis, specific treatment before use of corticosteroids is appointed. Nevertheless, perhaps, but only in certain cases to use a combination corticosteroids + specific treatment. At emergence of local intolerance, treatment has to be stopped. In case of use of drug in eyebrows, duration of treatment has to be limited as prolonged use leads to risk of a ptosis (because of negative impact on the muscle raising an eyelid), to glaucoma and converse effect. Lokatop of 0.1% contains sorbic acid or one of its salts and can cause local reactions of skin (for example, eczema). Pregnancy and the period of a lactation Lokatop of 0.1% should not be applied at pregnant women, except cases of obvious need (at accurate indications), it is necessary to weigh carefully potential risk for mother and a fruit and the expected advantage of treatment. Drug is emitted with milk therefore at drug use mothers should stop feeding by a breast of Feature of influence of medicine on ability to run the vehicle or potentially dangerous mechanisms the Overdose Symptoms does not influence: sharpening of side and system effects. Treatment: gradual cancellation of use of drug. However, at sharp drug withdrawal the risk of intense oppression of function of adrenal glands is possible therefore drug withdrawal has to be carried out under observation of the doctor. The form of release and packing On 30 g of drug place in a tuba from polyethylene with or without cannula. On 1 tuba together with the instruction for medical use in the state and Russian languages put in a box of cardboard. To Store storage conditions at a temperature not higher than 30 Store OS out of children’s reach! 3 years not to apply a period of storage after the termination of the expiration date specified on packing Prescription status According to the prescription of Proizvoditel Pierre Fabr Medikament Production, 45, Abel Hans Square, 92100 Boulogne, France the Owner of the registration certificate Pierre Fabr Dermatolodgi, France the Address of the organization accepting in the territory of the Republic of Kazakhstan claims from consumers on quality of products (goods): VIVA FARM LLP, Kazakhstan, 050030, Almaty, 2nd Ostroumova St., 33
Reviews
There are no reviews yet.